$6.71
2.91% yesterday
Nasdaq, Jul 23, 10:00 pm CET
ISIN
US00289Y1073
Symbol
ABEO

Abeona Therapeutics, Inc. Stock price

$6.71
+0.90 15.49% 1M
+1.46 27.81% 6M
+1.14 20.47% YTD
+1.58 30.80% 1Y
+2.42 56.41% 3Y
-67.04 90.90% 5Y
-140.79 95.45% 10Y
-9,930.79 99.93% 20Y
Nasdaq, Closing price Wed, Jul 23 2025
+0.19 2.91%
ISIN
US00289Y1073
Symbol
ABEO
Industry

Key metrics

Basic
Market capitalization
$343.3m
Enterprise Value
$278.4m
Net debt
positive
Cash
$84.2m
Shares outstanding
49.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 13.4
EV/Sales
- | 10.9
EV/FCF
negative
P/B
8.3
Financial Health
Equity Ratio
40.4%
Return on Equity
-144.8%
ROCE
-85.5%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$0.0 | $25.6m
EBITDA
$-66.6m | -
EBIT
$-69.6m | $-54.5m
Net Income
$-44.2m | $-20.8m
Free Cash Flow
$-63.0m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
-41.5% | -
EBIT
-40.9% | 15.1%
Net Income
42.4% | 67.4%
Free Cash Flow
-55.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -81.1%
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-1.3
Short interest
17.4%
Employees
136
Rev per Employee
$0.0
Show more

Is Abeona Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,026 stocks worldwide.

Abeona Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Abeona Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 33 33
47% 47%
-
- Research and Development Expense 37 37
23% 23%
-
-67 -67
42% 42%
-
- Depreciation and Amortization 3 3
28% 28%
-
EBIT (Operating Income) EBIT -70 -70
41% 41%
-
Net Profit -44 -44
42% 42%
-

In millions USD.

Don't miss a Thing! We will send you all news about Abeona Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Abeona Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
- Lucile Packard Children's Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics ® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - - ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - CLEVELAND,...
Neutral
PRNewsWire
10 days ago
MINNEAPOLIS , July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout...
Neutral
GlobeNewsWire
22 days ago
Cash resources totaled approximately $225 million as of June 30, 2025 Cash resources totaled approximately $225 million as of June 30, 2025
More Abeona Therapeutics, Inc. News

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Head office United States
CEO Vishwas Seshadri
Employees 136
Founded 1974
Website abeonatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today